Ondansetron
Generic Name: Ondansetron
Uses & Medical Indications
Prevention of nausea and vomiting associated with chemotherapy, radiation, or surgery
Chemotherapy-Induced Nausea/Vomiting (CINV), Postoperative Nausea/Vomiting (PONV)
Work Mechanism & Pharmacology
Patient Overview of Work Mechanism
Ondansetron works at the cellular level to correct underlying biochemical imbalances, reduce clinical symptoms, and support overall health.
Clinical Mechanism of Action (MoA)
Ondansetron exerts targeted therapeutic activity by interacting with specific cellular receptors, enzymatic pathways, or biological signaling cascades to relieve symptoms and restore physiological balance.
Dosage & Administration Guidelines
8 mg twice daily or 8-16 mg 30 mins before chemotherapy
0.15 mg/kg IV or weight-based oral dosing
Same as adult
24 mg/day orally; 16 mg/dose IV
No adjustment necessary
Maximum 8 mg/day in severe hepatic impairment
Side Effects & Safety Warnings
Headache, constipation, diarrhea, dizziness, fatigue
QT prolongation, serotonin syndrome, severe hypersensitivity
Use with apomorphine
Dose-dependent QT prolongation; avoid in congenital long QT syndrome
Interactions (Drugs, Food & Alcohol)
Apomorphine, QT-prolonging drugs (amiodarone, macrolides), serotonergic agents
N/A
No specific interaction
Identified Clinical Drug Interactions for Ondansetron:
Additive QT Interval Prolongation & Torsades de Pointes
Pregnancy & Breastfeeding Safety
Often used off-label for morning sickness; generally considered safe but consult OB/GYN
Use caution; excretion in milk is likely
Patient Counseling & Practical Advice
Let ODT dissolve on tongue. Drink fluids if constipated.
Take as soon as remembered if nauseous. Otherwise, skip.
ECG (in high-risk patients), potassium, magnesium
When to Seek Urgent Medical Attention
Seek immediate emergency medical care (call emergency services or proceed to the nearest emergency department) if you experience signs of a life-threatening allergic reaction (anaphylaxis: facial, lip, tongue, or throat swelling causing airway obstruction), severe cutaneous blistering with skin peeling, sudden intense chest pain, or symptoms of overdose.
Content for Ondansetron was synthesized from standardized public health monographs, official pharmacopoeias, and health authorities:
- Central Drugs Standard Control Organization (CDSCO) — National List of Essential Medicines
- World Health Organization (WHO) — Model List of Essential Medicines
- Indian Pharmacopoeia Commission (IPC) — Indian Pharmacopoeia Drug Monographs
- National Health Service (NHS) — Medicines A to Z Clinical Guidelines
The information provided on this website is for educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with any questions you may have regarding a medical condition.